International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (901-905), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Proper Diagnosis and Treatment Options of Follicular Lymphoma

[1]Alghanmi Mousa Wasal, [2]Alfifi Abdulaziz Hassan Y, [3]Hussain Hasan Jammal, [4]Dheifullah Mastoor AlZaidy, [5] Mohammed Ali K Muqri, [6]Ahmed Mayudh Almalki, [7]Ahmed Edah Alzhrani

Abstract: **The goal of this review is to highlight the most effective treatment for follicular lymphoma, however discussing different approaches of treatments but mostly to emphasize the efficient one. Three electronic databases (PubMed, Embase, and the Cochrane Library) were methodically looked for research studies evaluating the treatments for follicular lymphoma, released in English from approximately date 2016. Additional sources were recognized through searches of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA), and the bibliographies of included trials and current reviews. WW method is generally recommended for asymptomatic low tumor problem FL patients with advanced-stage disease, given that early systemic treatment has actually not shown benefits in OS compared to WW, and the progression-free survival and time to next treatment benefits of such techniques remain arguable. First-line rituximab monotherapy has shown really high action rates of 70 - 80%, and can produce long progression-free survival. The addition of rituximab to a number of chemotherapy routines enhanced the reaction rates, in a number of randomized controlled trials, combined rituximab plus chemotherapy (R-chemotherapy) demonstrated enhancements in total action rate, reaction duration and progression-free survival for untreated advanced-stage FL patients, and has actually shown total survival) benefits in some of these trials when compared with chemotherapy alone.**

Keywords: **American Society of Clinical Oncology (ASCO), European Hematology Association (EHA).**

1. INTRODUCTION

Follicular lymphoma (FL) is a common kind of non-Hodgkin's lymphoma (NHL), Follicular non-Hodgkin lymphoma (f-NHL) is a slow-growing (indolent) subtype of NHL that constitutes approximately 20-25% of all NHL and 70% of indolent lymphomas [(1)]. While f-NHL is considered incurable with currently available treatments, the 5-year survival rate is around 70% (2) with average survival being 8-10 years [(3,4)].

Most patients present with advanced-stage disease (phase III or IV) at diagnosis. Available choices for the preliminary management of FL include watchful waiting (WW; or initial active observation), radiotherapy, immunotherapy, single-agent chemotherapy, and mix chemotherapy. A preliminary publication from the NLCS trial suggested that in medical practice a wide range of management techniques are utilized and no single basic technique for the preliminary management of FL in the USA has actually been adopted [(5)]. Among more than 2700 patients enrolled at 265 sites, the initial technique was: WW in 17.7%, rituximab monotherapy in 13.9%, a medical trial in 6.1%, radiation treatment in 5.6%, chemotherapy in 3.2% and rituximab with chemotherapy in 51.9%. An existing technique for the initial management of patients with FL is shown in (Figure 1) (6). Methodical approaches for comparing the benefits of different management techniques are needed to resolve this scientific scenario where randomized contrasts of these techniques are not available or will not be possible in a timely style [(6)].

The Follicular Lymphoma International Prognostic Index (FLIPI) [(7)] was initially created in the period before the development of treatment with monoclonal antibodies, such as rituximab, a recently released research study by Buske et al [(8)] demonstrated that the FLIPI keeps its prognostic value even when patients are treated with routines consisting of rituximab. The National LymphoCare research study is continuing to evaluate treatments and outcomes in patients with

follicular lymphoma [9]. It is a potential observational research study conducted in the United States to evaluate prognosis, treatment, and outcomes in FL. In between 2004 and 2007, the study enrolled over 2700 patients recently identified with follicular lymphoma. Most (85%) of these patients were enrolled from community oncology sites, and only 15% were enrolled from scholastic sites [9].



Figure 1: Management strategies for follicular lymphoma

†Bulky, abdominal disease.
‡According to the Groupe d'Etude des Lymphomes Folliculaires criteria.
RIT: Radioimmunotherapy; RT: Radiotherapy.

Purpose of study:

The goal of this review is to highlight the most effective treatment for follicular lymphoma, however discussing different approaches of treatments but mostly to emphasize the efficient one.

2. METHODOLOGY

Three electronic databases (PubMed, Embase, and the Cochrane Library) were methodically looked for research studies evaluating the treatments for follicular lymphoma, released in English from approximately date 2016. Additional sources were recognized through searches of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA), and the bibliographies of included trials and current reviews. To determine research studies on the broad variety of disease states of interest handling follicular lymphoma were used. Browse terms included combinations of medical subject headings (MeSH) and disease terms limited to the title and abstract. The search was limited utilizing MeSH and title and abstract terms for interventions, particularly pharmacotherapy. The search was also limited to clinical research studies.

3. RESULTS

- ***Treatment options of Follicular lymphoma:***

Amongst low tumor concern advanced-stage FL patients, postponing preliminary chemotherapy treatment has been supported by the following issues: treatment would lead to negative effects hindering patients' quality of life, cumulative courses of treatment may impact the expediency of subsequent lines of treatment at relapse or change, and no significant clinical benefit arises from immediate treatment compared to the WW strategy [10,11,12,13]. For patients undergoing WW, the initiation of treatment is triggered by the existence of constitutional signs, crucial organ comprise, bone marrow involvement, quick progression and improvement as specified by the Groupe d'Etude des Lymphomes Folliculaires (GELF), BNLI or National Comprehensive Cancer Network (NCCN) requirements [14,15]. On the other hand, beginning

treatment at diagnosis might get rid of tumor resistance by treating the disease when it is more susceptible, and subsequently may enhance duration of response or progression-free survival (PFS) [10,11,12,13]. In a number of randomized regulated trials (RCTs), combined rituximab plus chemotherapy (R-chemotherapy) demonstrated enhancements in overall reaction rate (ORR), reaction duration and PFS for untreated advanced-stage FL patients, and has actually shown total survival (OS) benefits in some of these trials when compared with chemotherapy alone (**Table 1**) [16,17,18,19]. While randomized data provide evidence that chemotherapy routines given with rituximab provide benefits over the very same chemotherapy routine offered alone, there is little released information from randomized controlled scientific trials that compare R-chemotherapy routines to each other. The addition of rituximab to chemotherapy has ended up being common, but dispute stays concerning which patients are best matched for each R-chemotherapy mix [20,21,22,23].

Table 1: Adding rituximab to front-line chemotherapy improves response rates, progression-free and overall survival.

Regimen	n	CR (%)			PFS (%)		OS (%)		Ref.
		R-chemo	Chemo	End point (years)	R-chemo	Chemo	R-chemo	Chemo	
R-CHOP	428	44	35	2	82‡	64	95†	90	(17)
R-CHVP–IFN	358	63	34	5	52‡	37	84	79	(19)
R-CVP	201	50‡	25	4	71‡	40	87†	74	(18)
R-MCP	201	50‡	25	4	71‡	40	87†	74	(16)

†Statistically significant improvement for rituximab with chemotherapy compared with chemotherapy among patients who required therapy.
Chemo: Chemotherapy; CR: Complete response; OS: Overall survival; PFS: Progression-free survival; R-chemo: Combined rituximab plus chemotherapy.

Numerous studies have just recently demonstrated progression-free survival advantage and recommended possible total survival benefit when rituximab is combined with chemotherapy [16,17,18,24,25,26]. In a phase 2 research study by Hiddemann and colleagues that examined CHOP with and without rituximab,[17] R-CHOP was found to significantly lengthen the time to treatment failure (P<0.001) and to produce a substantially greater general reaction rate (ORR) (96% vs 90%; P=0.011) and extended period of remission (P=0.001). Additionally, total survival (OS) was considerably greater (P=0.016) in the R-CHOP group in the very first 3 years [17]. In another study by Hiddemann, patients with follicular lymphoma treated with interferon and R-CHOP as a preliminary therapy had a considerably longer PFS compared to those treated with CHOP (63% vs 84%, P=0.0004) [24]. In a study comparing CHVP-I (cyclophospamide, doxorubicin, prednisone, vindesine and interferon-alpha) with and without rituximab, event-free survival (EFS) and OS were significantly higher in the R-CHVP-I arm (81% vs 62%, P=0.002; and 91% vs 84%, P=0.029, respectively) [25]. A research study comparing CVP (vincristine, cyclophosphamide, and prednisone) with and without rituximab [18] found significant improvements in overall and complete reaction rates in the R-CVP arm (81% vs 57%, and 41% vs 10%, respectively, P<0.0001). Patients on the R-CVP arm also had significantly extended time to development (P<0.0001) and a longer median time to treatment failure (P <0.0001). A 2006 follow-up to that research study, [16] discovered a substantially longer time to progression or death in the R-CVP arm (34 months vs 15 months, P<0.001). Patients in the R-CVP arm likewise had actually considerably improved OS (P=0.03). In a research study comparing MCP (prednisolone, chlorambucil, and mitoxantrone) with and without rituximab, Herold and associates [26] discovered that patients in the R-MCP arm had considerably greater action rates (92.4% vs 75%, P=0.0004) and complete actions (49.5% vs 25%, P=0.0009). Average PFS and EFS were not reached in the R-MCP arms but still reached significance (P<0.0001 for average PFS and EFS). These studies show the advantage of including rituximab when treating follicular lymphoma patients with chemotherapy.

- **Maintenance proper treatment of Follicular Lymphoma:**

FL patients with a long disease history and sluggish development are more conscious different treatments. Hence, upkeep treatment is suitable for these patients after remission induction. Various medical studies and meta-analysis outcomes have shown that, for FL patients after front-line treatment or one more remission induction of regression, the maintenance treatment via single-agent rituximab improves long-lasting survival [27,28]. For that reason, the recommended treatment for patients being at first treated or relapsed patients after induction chemotherapy and complete remission (CR) or partial remission (PR) is one maintenance treatment by single-agent rituximab every 2 to 3 months, for an overall of 2 years. The

probability of infection can increase after maintenance treatment. Close follow-up and observation should be given to liver disease B patients [29].

4. CONCLUSION

At present, a WW method is generally recommended for asymptomatic low tumor problem FL patients with advanced-stage disease, given that early systemic treatment has actually not shown benefits in OS compared to WW, and the progression-free survival and time to next treatment benefits of such techniques remain arguable. First-line rituximab monotherapy has shown really high action rates of 70-- 80%, and can produce long progression-free survival. The addition of rituximab to a number of chemotherapy routines enhanced the reaction rates, in a number of randomized controlled trials, combined rituximab plus chemotherapy (R-chemotherapy) demonstrated enhancements in total action rate, reaction duration and progression-free survival for untreated advanced-stage FL patients, and has actually shown total survival) benefits in some of these trials when compared with chemotherapy alone

REFERENCES

[1] The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909–3918.

[2] Altekruse S, Kosary C, Krapcho M, et al. Bethesda, MD: National Cancer Institute; 2010. SEER cancer statistics review, 1975-2007.

[3] Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20:75–88.

[4] Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019–5026.

[5] Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J. Clin. Oncol. 2009;27(8):1202–1208.

[6] Chen Q, Ayer T, Nastoupil LJ, et al. Initial management strategies for follicular lymphoma. *International journal of hematologic oncology*. 2012;1(1):35-45. doi:10.2217/ijh.12.7.

[7] Halaas JL, Teruya-Feldstein J, Filippa DA, Chaya M, Naresh KN, Zelenetz AD. The Follicular Lymphoma International Prognostic Index (FLIPI) Is superior to WHO/REAL histological grade for identifying high-risk patients: a retrospective review of the MSKCC experience in 260 patients with follicular lymphoma. Blood. 2004;104 892a (abstr 3268)

[8] Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504–1508.

[9] An observational study of treatment, outcomes, and prognosis in patients with follicular non-Hodgkin's lymphoma. No authors listed. http://clinicaltrials.gov/ct2/show/NCT00097565.

[10] Dreyling M, Buske C, Unterhalt M, Hiddemann W. Risk-adapted treatment of follicular non-Hodgkin lymphoma: current standards and future strategies. Haematologica. 2007;92(Extra 1):19–24.

[11] Czuczman MS. Controversies in follicular lymphoma: “who, what, when, where, and why?”(not necessarily in that order) Hematology Am. Soc. Hematol. Educ. Program. 2006;2006:303–310.

[12] Gandhi MK, Marcus RE. Follicular lymphoma: time for a re-think? Blood Rev. 2005;19(3):165–178.

[13] Tan D, Horning SJ. Follicular lymphoma: clinical features and treatment. Hematol. Oncol. Clin. North Am. 2008;22(5):863–882.

[14] Ardeshna KM, Smith P, Norton A, et al. British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522.

[15] Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 1997;15(3):1110–1117.

[16] Herold M, Haas A, Srock S, et al. East German Study Group Hematology and Oncology Study Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 2007;25(15):1986–1992.

[17] Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–3732.

[18] Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417–1423.

[19] Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824–4831.

[20] Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). ASCO Meeting Abstracts 30; 2012. Abstract 8006.

[21] Morschhauser F, Seymour J, Feugier P, et al. Impact of induction chemotherapy regimen on response, safety and outcome in the Prima Study. Ann. Oncol. 2011;22(Suppl. 4):022.

[22] Nastoupil L, Sinha R, Byrtek M, et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Blood. 2011;118(21).

[23] Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin. Lymphoma Myeloma Leuk. 2010;10(6):414–423.

[24] Hiddemann W, Forstpointner R, Kneba M, et al. The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: Results of two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG) Blood. 2004;104 50a.

[25] Foussard C, Mounier N, Van Hoof A, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts) J Clin Oncol. 2006;24 abstr 7508.

[26] Marcus RE, Solal-Celigny P, Imrie K, et al. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkins lymphoma (NHL) Blood. 2006;108 146a (abstr 481)

[27] Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-1614

[28] Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51

[29] Huang YH, Lin HC, Lee SD. Management of chemotherapy-induced hepatitis B virus reactivation. J Chin Med Assoc 2012;75:359-362